Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 Shares of Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $107.24, for a total transaction of $2,144,800.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $82,336,727.20. This trade represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

• On Wednesday, September 9th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $107.43, for a total transaction of $2,148,600.00.
• On Tuesday, August 18th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $104.18, for a total transaction of $2,083,600.00.
• On Wednesday, July 8th, Helen Torley sold 1,923 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $79.77, for a total transaction of $153,397.71.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO traded up $0.20 on Friday, reaching $107.20. The company’s stock had a trading volume of 861,533 shares, compared to its average volume of 1,560,954. The company has a 50-day simple moving average of $93.73 and a 200 day simple moving average of $76.97. Halozyme Therapeutics, Inc. has a 52-week low of $61.22 and a 52-week high of $111.15. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. The company has a market cap of $12.17 billion, a P/E ratio of 32.00, a PEG ratio of 0.41 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.49. The firm had revenue of $481.00 million for the quarter, compared to analysts’ expectations of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business’s revenue was up 47.7% compared to the same quarter last year. During the same period in the prior year, the company earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 8.25 EPS for the current fiscal year.

Institutional Trading of Halozyme Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Talon Private Wealth LLC bought a new stake in Halozyme Therapeutics in the second quarter worth about $839,000. Sequoia Financial Advisors LLC purchased a new position in shares of Halozyme Therapeutics during the second quarter valued at approximately $359,000. Tidal Investments LLC grew its stake in shares of Halozyme Therapeutics by 13.5% during the second quarter. Tidal Investments LLC now owns 190,305 shares of the biopharmaceutical company’s stock valued at $14,895,000 after buying an additional 22,707 shares during the last quarter. WINTON GROUP Ltd grew its stake in shares of Halozyme Therapeutics by 704.6% during the second quarter. WINTON GROUP Ltd now owns 60,348 shares of the biopharmaceutical company’s stock valued at $4,723,000 after buying an additional 52,848 shares during the last quarter. Finally, Engineers Gate Manager LP raised its holdings in shares of Halozyme Therapeutics by 6.7% in the second quarter. Engineers Gate Manager LP now owns 46,172 shares of the biopharmaceutical company’s stock worth $3,614,000 after buying an additional 2,889 shares during the period. 97.79% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Citizens Jmp upped their price objective on Halozyme Therapeutics from $92.00 to $93.00 and gave the company a “market outperform” rating in a research report on Friday, August 7th. Leerink Partners raised Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $83.00 to $110.00 in a research report on Friday, August 7th. Wells Fargo & Company boosted their target price on Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. Finally, UBS Group restated a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Nine equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $91.20.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company’s primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.